The global aging population is witnessing an alarming rise in the number of cases of eye disease, with retinal issues affecting the lives of over 250 million people worldwide. Patients with vision-threatening conditions such as macular degeneration may receive injections in their eyes as often as every month to prevent blindness. While effective, maintaining these treatment regimens creates a huge burden for patients and their caregivers, as well as for healthcare providers. Join us to learn how a team including an ocular biomaterials researcher and a vitreoretinal surgeon, both from The Ohio State University, are developing technology to significantly reduce this treatment burden by providing delivery of therapeutics from a tunable extended-release capsule.